keyword
Keywords Anticoagulation plus double an...

Anticoagulation plus double antiplatelet in acute myocardial

https://read.qxmd.com/read/34883097/the-role-of-triple-antithrombotic-therapy-in-patients-with-atrial-fibrillation-undergoing-percutaneous-coronary-intervention
#1
REVIEW
Alexander C Fanaroff, Renato D Lopes
Dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel forms the backbone of secondary prevention in patients with acute coronary syndromes (ACS) or who undergo percutaneous coronary intervention (PCI), but in patients with atrial fibrillation (AF), oral anticoagulation (OAC) is superior to antiplatelet therapy for the prevention of stroke and systemic embolism. Patients with AF who undergo PCI or have an ACS event therefore have an indication for both OAC and DAPT, so-called triple antithrombotic therapy...
November 2021: Progress in Cardiovascular Diseases
https://read.qxmd.com/read/22795814/atrial-fibrillation-and-acute-myocardial-infarction-antithrombotic-therapy-and-outcomes
#2
COMPARATIVE STUDY
Renato D Lopes, Li Li, Christopher B Granger, Tracy Y Wang, JoAnne M Foody, Marjorie Funk, Eric D Peterson, Karen P Alexander
BACKGROUND: Atrial fibrillation guidelines recommend long-term use of warfarin according to a patient's predicted risk of stroke. After acute myocardial infarction, however, combining warfarin and antiplatelet medications poses challenges. METHODS: By using data from more than 69,255 patients with acute myocardial infarction who were enrolled in the National Cardiovascular Data Registry's Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines at 309 hospitals from July 1, 2008, to September 30, 2009, we describe the characteristics and outcomes of the population with myocardial infarction with atrial fibrillation diagnosed within 2 weeks before index myocardial infarction admission (7...
September 2012: American Journal of Medicine
https://read.qxmd.com/read/21570509/rationale-and-design-of-the-anti-xa-therapy-to-lower-cardiovascular-events-in-addition-to-standard-therapy-in-subjects-with-acute-coronary-syndrome-thrombolysis-in-myocardial-infarction-51-atlas-acs-2-timi-51-trial-a-randomized-double-blind-placebo-controlled
#3
RANDOMIZED CONTROLLED TRIAL
C Michael Gibson, Jessica L Mega, Paul Burton, Shinya Goto, Freek Verheugt, Christoph Bode, Alexei Plotnikov, Xiang Sun, Nancy Cook-Bruns, Eugene Braunwald
BACKGROUND: Although therapy with aspirin or aspirin plus a thienopyridine reduces the incidence of long-term adverse cardiovascular events among patients with acute coronary syndrome (ACS), there remains a significant residual risk of cardiovascular death, recurrent myocardial infarction (MI), and stroke. In a phase 2 trial (ClinicalTrials.gov NCT00402597) in which the addition of the factor Xa inhibitor rivaroxaban was compared with placebo, among ACS patients receiving either aspirin alone or dual-antiplatelet therapy with aspirin and a thienopyridine, the end point of death, MI, or stroke compared with placebo was reduced (87/2331 [3...
May 2011: American Heart Journal
https://read.qxmd.com/read/19470889/apixaban-an-oral-direct-selective-factor-xa-inhibitor-in-combination-with-antiplatelet-therapy-after-acute-coronary-syndrome-results-of-the-apixaban-for-prevention-of-acute-ischemic-and-safety-events-appraise-trial
#4
RANDOMIZED CONTROLLED TRIAL
John H Alexander, Richard C Becker, Deepak L Bhatt, Frank Cools, Filippo Crea, Mikael Dellborg, Keith A A Fox, Shaun G Goodman, Robert A Harrington, Kurt Huber, Steen Husted, Basil S Lewis, Jose Lopez-Sendon, Puneet Mohan, Gilles Montalescot, Mikhail Ruda, Witold Ruzyllo, Freek Verheugt, Lars Wallentin
BACKGROUND: After an acute coronary syndrome, patients remain at risk of recurrent events. Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also poses a risk of bleeding. METHODS AND RESULTS: Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) was a phase 2, double-blind, placebo-controlled, dose-ranging study. Patients (n=1715) with recent ST-elevation or non-ST-elevation acute coronary syndrome were randomized to 6 months of placebo (n=611) or 1 of 4 doses of apixaban: 2...
June 9, 2009: Circulation
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.